ArticleNPJ precision oncology2026
Translating spatial transcriptomic signatures in adenosquamous carcinoma into bulk prognostic biomarkers in lung adenocarcinoma: a bottom-up approach.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spatial Transcriptomics Recontextualizes the Cellular Environment of Conjunctival Melanoma.medRxiv : the preprint server for health sciences · 2026Article
- Solute carrier transporters as metabolic gatekeepers in tumor-microenvironment crosstalk.Acta pharmacologica Sinica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Spatial transcriptomics enables the detection of rare or transitional tumor states not captured by bulk transcriptomics or immunohistochemistry (IHC). However, translating these spatially defined states into clinically relevant biomarkers is challenging, because signals from minor populations are underrepresented or masked in bulk data. Lung adenosquamous carcinoma (ASC), containing intermixed adenocarcinoma and squamous components, provides a model to study lineage transitions and poorly differentiated states unresolved in bulk datasets. Spatial transcriptomic profiling of ASC was integrated with TTF-1 and p40 IHC to detect tumor populations lacking these markers. Gene signatures from IHC-negative populations were projected onto bulk lung adenocarcinoma datasets to assess prognostic relevance. We implemented a color-space uniform manifold approximation and projection visualization (RGB-UMAP) to enhance the spatial mapping of rare transcriptional states that were unresolved by conventional clustering. We identified a TTF-1/p40-negative tumor cell population with a hybrid adenocarcinoma-squamous expression pattern and upregulation of SLC2A1 (GLUT1). RGB-UMAP clarified these states and distinguished them from normal epithelial cells. In bulk lung adenocarcinoma cohorts, high SLC2A1 expression stratified patients with poorer survival. This study demonstrates a bottom-up biomarker discovery strategy translating spatially defined, IHC-negative tumor cell populations in ASC into stratifiers for lung adenocarcinoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.